|
|
 |
|
Viewing report
|
|
|
|
The HIV Market Outlook to 2016
Business Insights, Aug 2011, Pages: 100
This report provides comprehensive coverage of the HIV market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the HIV market. It also identifies products in late stage development and forecasts their expected sales performance.
Features and benefits
- Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
- Compare the franchises of the leading companies in HIV, and understand how the market share of these companies will change.
- Evaluate pipeline compounds for the treatment of HIV and determine which products will provide the greatest revenue growth.
- Understand the market dynamics and interactions between the key drug classes used in the treatment of HIV.
- Forecast the performance of the leading marketed and pipeline products through to 2016.
Highlights
In terms of sales, the US dominated the global HIV market, accounting for just over 50% of sales in 2010. Collectively, the leading pharmaceutical markets of the EU were the second largest HIV market with a market share of just over 33%. The countries with very high endemicity of HIV actually only account for very small market shares.
The current market for HIV treatment is dominated by once-daily regimens. There is a strong trend towards regimen simplification and reduced pill burden, which has resulted in the rapid penetration of several once daily treatment options. To this end Gilead is developing a Quad Pill which contains four active ingredients the first such product.
Gilead was the leading company in the 2010 recording sales of over $6bn at a Y-o-Y growth of over 13%. Gilead’s performance in 2010 was very strong, capturing over 35% of the global HIV market. This strong performance was largely due to the company’s leading NRTI product, Atripla which posted 2010 sales of $3bn at a Y-o-Y growth of 22.9%.
Your key questions answered
- Who were the leading players in the HIV market in 2010 and which products were driving their performance?
- Which products are leading each of the leading drug classes for the treatment of HIV and how will this change through to 2016?
- Which pipeline products are best positioned to drive continued market growth for their developers?
- Which of the seven major markets have the greatest prevalence of HIV?
- How will generic penetration impact the sales of products that are set to lose patent protection in the forecast period?'
|
|
|
|
